Trials / Completed
CompletedNCT02227797
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to identify the optimal dose of voriconazole, an anti-fungal drug often used in people undergoing stem cell transplant. An optimal dose level is one level that provides a good blood level (concentration) of voriconazole without too much toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Voriconazole | 6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients |
Timeline
- Start date
- 2015-01-19
- Primary completion
- 2017-09-08
- Completion
- 2019-03-01
- First posted
- 2014-08-28
- Last updated
- 2019-04-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02227797. Inclusion in this directory is not an endorsement.